Vtv Therapeutics logo

Vtv Therapeutics Share Price (NASDAQ: VTVT)

$15.75

0.31

(2.01%)

Live

Last updated on

Check the interactive Vtv Therapeutics Stock chart to analyse performance

Vtv Therapeutics Inc Key Stats

Check Vtv Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$15.44
Open
$15.55
Market Capitalization
$40.4M
Today's Volume
$5.7K
Revenue TTM
$17.0K
EBITDA
$-25.6M
Earnings Per Share (EPS)
$-2.92
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-209.04%

Stock Returns calculator for Vtv Therapeutics Stock including INR - Dollar returns

The Vtv Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vtv Therapeutics investment value today

Current value as on today

₹1,05,686

Returns

₹5,686

(+5.69%)

Returns from Vtv Therapeutics Stock

₹1,613 (+1.61%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Vtv Therapeutics Stock

18%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Vtv Therapeutics Stock from India on INDmoney has increased by 18% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Vtv Therapeutics Inc

  • Name

    Holdings %

  • Samsara BioCapital, LLC

    7.90%

  • FMR Inc

    6.81%

  • Baker Bros Advisors LP

    3.72%

  • Vanguard Group Inc

    1.65%

  • Northern Trust Corp

    0.60%

  • Geode Capital Management, LLC

    0.48%

Analyst Recommendation on Vtv Therapeutics Stock

Rating
Trend

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 7 Wall street analysts offering stock ratings for Vtv Therapeutics(by analysts ranked 0 to 5 stars)

Vtv Therapeutics Share Price Target

What analysts predicted

Upside of 125.4%

Target:

$35.50

Current:

$15.75

Vtv Therapeutics share price target is $35.50, a slight Upside of 125.4% compared to current price of $15.75 as per analysts' prediction.

Vtv Therapeutics Stock Insights

  • Price Movement

    In the last 3 months, VTVT stock has moved down by -26.6%
  • VTVT vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 53.5%
  • VTVT vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 169.3%
  • Price to Sales

    ForVTVT every $1 of sales, investors are willing to pay $2548.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Vtv Therapeutics Technicals Summary

Sell

Neutral

Buy

Vtv Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Vtv Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Vtv Therapeutics Inc logo
-9.34%
-20.78%
-0.39%
-68.36%
-82.92%
Regeneron Pharmaceuticals, Inc. logo
6.39%
-14.65%
-51.51%
-6.14%
-7.82%
Beone Medicines Ltd logo
10.08%
34.96%
66.94%
83.8%
36.85%
Vertex Pharmaceuticals Incorporated logo
-14.33%
-15.0%
-19.52%
31.35%
45.44%
Alnylam Pharmaceuticals, Inc. logo
40.06%
79.56%
63.55%
107.86%
227.15%

About Vtv Therapeutics Inc

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
Organization
Vtv Therapeutics
Employees
23
CEO
Mr. Paul J. Sekhri M.Sc.
Industry
Health Technology

Key Management of Vtv Therapeutics Inc

NameTitle
Mr. Paul J. Sekhri M.Sc.
CEO, President & Chairman of the Board
Dr. Michael Steven Tung M.B.A., M.D.
Executive VP & CFO
Mr. Barry K. Brown
Chief Accounting Officer
Dr. Carmen Valcarce Ph.D.
Chief Scientific Officer & Executive VP
Ms. Elizabeth M. Keiley
Executive VP & General Counsel
Mr. Richard S. Nelson
Executive VP of Corporate Development & Director
Dr. Thomas Strack M.D., Ph.D.
Chief Medical Officer
Mr. Martin Lafontaine
Chief Commercial Officer

Important FAQs about investing in VTVT Stock from India :

What is Vtv Therapeutics share price today?

Vtv Therapeutics share price today is $15.75 as on . Vtv Therapeutics share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Vtv Therapeutics share?

Vtv Therapeutics share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Vtv Therapeutics stock price today, is trending at $15.75, lower by 41.65% versus the 52 week high.

How to invest in Vtv Therapeutics Stock (VTVT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Vtv Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vtv Therapeutics Shares that will get you 0.0952 shares as per Vtv Therapeutics share price of $15.75 per share as on August 18, 2025 at 10:25 PM IST.

What is the minimum amount required to buy Vtv Therapeutics Stock (VTVT) from India?

Indian investors can start investing in Vtv Therapeutics (VTVT) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Vtv Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Vtv Therapeutics share’s latest price of $15.75 as on August 18, 2025 at 10:25 PM IST, you will get 0.6349 shares of Vtv Therapeutics. Learn more about fractional shares .

What are the returns that Vtv Therapeutics has given to Indian investors in the last 5 years?

Vtv Therapeutics stock has given -82.92% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?